GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

lunsekimig   Click here for help

GtoPdb Ligand ID: 14473

Synonyms: F027400161 [2] | SAR-443765 | SAR443765
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lunsekimig (SAR443765) is a single chain nanobody that is constructed of five linked antibody (VHH) domains that simultaneously bind the inflammatory targets thymic stromal lymphopoietin (TSLP) and IL-13, and human serum albumin (ALB). The peptide sequence provided in the INN record matches SEQ ID No 1 in patent US11208476 [2], which equates to clone F027400161 therein.
No information available.
Summary of Clinical Use Click here for help
Lunsekimig (SAR443765) is a clinical candidate for the treatment of chronic inflammaroty diseases. Efficacy has been noted in respiratory diseases [1], but the phase 2b Velvet study in atopic dermatitis missed its primary endpoint (reduction in disease severity; April 2026).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06676319 Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma Phase 2 Interventional Sanofi
NCT06914908 Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study Phase 2 Interventional Sanofi
NCT07190222 Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype Phase 3 Interventional Sanofi
NCT06790121 A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis Phase 2 Interventional Sanofi The VELVET study.